Thousands of women with breast cancer may be spared chemotherapy, landmark study shows

Infusion pump feeding IV drip into patients arm focus on needle

The 12-year TAILORx study, co-authored by a VCU Massey Cancer Center physician-researcher, shows chemotherapy does not increase disease-free survival rates for women with early stage breast cancer and an intermediate risk of recurrence.

Seventy percent of women with the most common type of newly diagnosed breast cancer can now be identified and safely skip chemotherapy, according to the results of a landmark 12-year clinical research study.

Data from the Trial Assigning Individualized Options for Treatment show that chemotherapy does not increase disease-free survival rates for women with early stage breast cancer and an intermediate risk of recurrence determined by the Oncotype DX Recurrence Score test. The study was designed to more precisely determine the effect of chemotherapy, if any, for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node-negative breast cancer.

The findings, recently presented at the American Society of Clinical Oncology annual meeting in Chicago and published in the New England Journal of Medicine, are expected to inform treatment decisions for thousands of breast cancer patients.

Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *